Différences spécifiques liées au genre chez les patients atteints de rhumatisme psoriasique recevant de l'ustekinumab ou un inhibiteur du facteur de nécrose tumorale : Données en situation réelle
Rheumatology (Oxford) doi:10.1093/rheumatology/kead089.
Real-world data from the PsABio study indicated that females with PsA had more severe disease than males before the initiation of treatment. While both genders experienced treatment related improvements, fewer females than males were able to achieve a favourable disease state within 12 months. Treatment discontinuation and switching were also higher in females than males, due to lower efficacy and adverse events.